eRA Information: New Mandatory Award Condition for RADx-UP Grantees for Specific NOSIs/FoAs

A new mandatory award condition has been added for Rapid Acceleration of Diagnostics-UP awards (RADx-UP) for grantees for specific Notice of Special Interest (NOSI)/Funding Opportunity Announcements (FoAs). The award condition notes that compliance with FDA Emergency Use Authorized (EUA) and FDA Clinical Laboratory Improvement Amendments (CLIA) is required of all RADx-UP projects funded under these NOSIs/FoAs.

This term will appear under Section IV (Specific Award Conditions) in the Notice of Award for the following NOSIs and FoAs, following an eRA release today:

Here is the specific award condition:

SECTION IV – SPECIFIC AWARD CONDITIONS

Compliance with FDA Emergency Use Authorized (EUA) and FDA Clinical Laboratory Improvement Amendments (CLIA) is required of all RADx-UP projects: